Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)60.50bn
- Net income in CHF8.28bn
- Incorporated1966
- Employees103.25k
- LocationRoche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
- Phone+41 616881111
- Websitehttps://www.roche.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | 23.12bn | 4.80bn | 108.89bn | 17.60k | 23.01 | 7.07 | 15.49 | 4.71 | 4.73 | 4.73 | 22.79 | 15.39 | 0.5098 | 3.45 | 6.35 | 1,632,671.00 | 10.58 | 5.26 | 13.63 | 6.38 | 78.29 | 78.47 | 20.76 | 12.54 | 1.23 | 7.80 | 0.5667 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Pfizer Inc | 50.25bn | 6.33bn | 112.43bn | 81.00k | 17.83 | 1.55 | 9.45 | 2.24 | 1.38 | 1.38 | 10.95 | 15.89 | 0.2911 | 1.46 | 5.47 | 771,148.10 | 3.68 | 7.45 | 4.49 | 9.43 | 74.57 | 69.10 | 12.64 | 20.37 | 0.9604 | 12.26 | 0.4066 | 64.22 | 6.84 | 9.10 | 275.82 | -5.27 | 2.32 | 3.13 |
| Amgen Inc | 27.46bn | 4.77bn | 129.03bn | 28.00k | 27.22 | 25.84 | 13.90 | 4.70 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Merck & Co Inc | 51.43bn | 14.03bn | 164.69bn | 75.00k | 11.87 | 4.24 | 9.26 | 3.20 | 6.87 | 6.87 | 25.19 | 19.21 | 0.5786 | 2.31 | 5.77 | 852,293.30 | 15.79 | 9.52 | 20.46 | 12.64 | 77.07 | 73.47 | 27.30 | 17.87 | 1.16 | 23.90 | 0.4186 | 72.96 | 6.74 | 10.40 | 4,589.59 | 24.64 | -0.5885 | 6.66 |
| AstraZeneca plc | 44.24bn | 6.25bn | 172.68bn | 94.30k | 27.81 | 5.23 | 16.67 | 3.90 | 3.71 | 3.71 | 26.23 | 19.73 | 0.5273 | 1.73 | 4.52 | 434,626.00 | 7.46 | 4.32 | 10.35 | 5.95 | 82.36 | 80.22 | 14.15 | 9.39 | 0.6954 | 10.42 | 0.4348 | 107.68 | 18.03 | 17.27 | 18.14 | 39.43 | 13.27 | 1.20 |
| Novo Nordisk A/S | 37.89bn | 13.08bn | 179.68bn | 77.41k | 18.06 | 13.59 | 12.09 | 4.74 | 23.48 | 23.48 | 68.03 | 31.21 | 0.7693 | 1.24 | 4.79 | 3,972,910.00 | 26.55 | 27.72 | 54.15 | 55.74 | 84.33 | 84.25 | 34.51 | 34.12 | 0.5571 | 47.34 | 0.4615 | 50.11 | 25.03 | 18.94 | 20.68 | 20.99 | 35.50 | 22.25 |
| Novartis AG | 42.78bn | 10.34bn | 198.18bn | 75.88k | 18.27 | 5.96 | 13.02 | 4.63 | 5.14 | 5.14 | 21.23 | 15.75 | 0.5475 | 2.24 | 6.47 | 563,810.40 | 13.24 | 9.80 | 19.31 | 13.08 | 75.66 | 73.76 | 24.18 | 24.42 | 0.6097 | 17.41 | 0.4478 | 66.42 | 10.85 | 1.24 | 39.37 | 10.83 | 11.06 | 4.83 |
| Roche Holding AG | 60.50bn | 8.28bn | 209.64bn | 103.25k | 24.90 | 6.43 | 16.63 | 3.47 | 10.32 | 10.32 | 75.43 | 39.94 | 0.6293 | 2.06 | 5.42 | 585,913.70 | 9.56 | 14.48 | 13.91 | 22.51 | 73.91 | 71.97 | 15.19 | 21.43 | 1.20 | 15.67 | 0.4894 | 64.02 | 3.03 | -0.318 | -28.01 | -9.32 | 0.4574 | 1.51 |
| AbbVie Inc | 46.15bn | 3.34bn | 272.01bn | 55.00k | 81.61 | 238.08 | 26.81 | 5.89 | 2.35 | 2.35 | 32.39 | 0.804 | 0.4025 | 3.83 | 4.70 | 1,043,036.00 | 2.95 | 5.44 | 4.06 | 7.09 | 70.69 | 68.89 | 7.33 | 13.73 | 0.6359 | 7.80 | 0.9795 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 7.69 |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 01 Jul 2025 | 26.71m | 3.80% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 26.24m | 3.73% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 18.71m | 2.66% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 14.62m | 2.08% |
| Z�rcher Kantonalbank (Investment Management)as of 30 May 2025 | 10.38m | 1.48% |
| Geode Capital Management LLCas of 10 Jul 2025 | 8.23m | 1.17% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 6.97m | 0.99% |
| BlackRock Asset Management Deutschland AGas of 04 Jul 2025 | 5.67m | 0.81% |
| Pictet Asset Management SAas of 31 May 2025 | 4.71m | 0.67% |
| MFS International (UK) Ltd.as of 31 May 2025 | 4.20m | 0.60% |
